ArriVent BioPharma Appoints Dr. Merdad Parsey to Board

By Bobby Samwell • Monday, April 28 10:07 • Permanent Link

Arrivent Biopharma, a clinical-stage biopharmaceutical company, has recently appointed Dr. Merdad Parsey, M.D., Ph.D., to its board of directors. Dr. Parsey has extensive executive experience in leading global clinical development in the biopharmaceutical industry, having most recently served as the Chief Medical Officer and Executive Vice President of Gilead Sciences, Inc.

Arrivent's Chairman and CEO, Bing Yao, expressed excitement about Dr. Parsey joining the board, highlighting his track record in driving therapeutic innovation and strategic growth in the pharmaceutical and biotech sectors. Dr. Parsey's appointment comes at a crucial time for Arrivent as the company progresses towards the registration of Firmonertinib and advances its pipeline of next-generation antibody drug conjugates (ADC).

Prior to joining Arrivent, Dr. Parsey held significant positions at Genentech, Inc., a member of the Roche Group, including Senior Vice President in Genentech Research and Early Development. He also served as President and CEO of 3-V Biosciences, Inc., now known as Sagimet Biosciences, Inc., and has been a member of the board of directors since 2010. His earlier career involved roles at Sepracor, Inc., Regeneron Pharmaceuticals, Inc., and Merck, Inc., as well as serving as an assistant professor of medicine and director of critical care medicine at New York University School of Medicine.

Arrivent Biopharma is focused on the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. The company aims to leverage its team's deep drug development experience to maximize the potential of its lead development candidate, Firmonertinib, and advance a pipeline of novel therapeutics, including next-generation antibody drug conjugates, through approval and commercialization. As a result of these announcements, the company's shares have moved 0.5% on the market, and are now trading at a price of $20.93. For the full picture, make sure to review ArriVent BioPharma's 8-K report.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.